
Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.

Join Dr. Celeste Porsbjerg as she discussed on how type 2 inflammation may lead to airway remodeling in asthma, exploring the pathophysiologic mechanisms, that ultimately lead to structural changes and irreversible loss of lung function

Join Dr. Hanania to understand how to identify patients at risk of fixed airway obstruction in clinical settings.

Join Klaus Rabe, MD, PhD, FERS; Celeste Porsberg, MD, PhD; and Mario Castro, MD, MPH, for a symposium on airway remodeling in severe asthma patients.
Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.

Join Dr. Celeste Porsbjerg as she discusses on how IL-13 contributes to mucus plugging in asthma.

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.

Dr. Paller presents the Pediatric Eczema Elective Registry (PEER) findings, which suggest early-onset of AD is associated with higher risk of persistence of disease.

Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in patients with asthma.